Cholesterol, Beyond LDL
ApoB, particle number, and what actually predicts risk
Cholesterol is the most talked-about number in cardiovascular prevention, and also one of the most commonly misunderstood. The core reframe worth internalising: it's not the total mass of cholesterol in your blood that drives atherosclerosis — it's the number of atherogenic particles carrying it.
Why Particle Number Matters More Than Cholesterol Mass
Each LDL (low-density lipoprotein) particle carries exactly one molecule of apolipoprotein B (ApoB) on its surface — as does each VLDL (very-low-density lipoprotein) and other atherogenic lipoprotein particle. A narrative review of the underlying atherosclerosis science argues that it's the number of these ApoB-carrying particles entering the artery wall, not the total cholesterol mass they happen to be carrying, that principally drives plaque formation — meaning ApoB is, in a mechanistic sense, closer to "cause" than LDL cholesterol is[4]. Two people can have identical LDL cholesterol numbers but meaningfully different particle counts, because some LDL particles are smaller and carry less cholesterol per particle — in that scenario, the person with more, smaller particles carries higher genuine risk despite the identical LDL-C reading.
What This Means Practically
ApoB is not on most standard panels — it needs to be requested specifically, and it's an inexpensive, widely available blood test.
LDL cholesterol remains useful and is still what most large clinical trials (including the statin trials in Section 12) were built around — it's not being replaced, but ApoB adds real precision, particularly for anyone with high triglycerides or metabolic syndrome, where LDL and ApoB commonly diverge.
Target: below 80 mg/dL for most people, with lower targets (below 60 mg/dL) typically recommended for those already at higher cardiovascular risk.
HDL: Less Straightforward Than "Good Cholesterol"
HDL (high-density lipoprotein) cholesterol has long been labelled "good cholesterol" because higher levels are associated with lower cardiovascular risk in observational data. The relationship is genuinely more complicated than that label suggests: drug trials specifically designed to raise HDL pharmacologically have largely failed to reduce cardiovascular events, which has led most of the field to treat HDL as more of a risk marker than a direct causal protective factor in its own right. Practically, this means chasing a higher HDL number through supplementation isn't a validated strategy — the levers that raise HDL naturally (exercise, not smoking, moderate alcohol) are the same fundamentals that help everything else in this guide anyway.
Section takeaway
ApoB — the count of atherogenic particles, not the mass of cholesterol they carry — is the more mechanistically accurate predictor of cardiovascular risk, and it's a simple, inexpensive test most people never think to request. LDL remains genuinely useful; ApoB adds precision on top of it, not a replacement for it.